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Cord blood transplantation (CBT) is curative for many patients with hematologic malignancies but is
associated with delayed immune recovery and an increased risk of viral infections compared with HLA-
matched bone marrow or peripheral blood progenitor cell transplantation. In this study we evaluated
the signiﬁcance of lymphocyte recovery in 125 consecutive patients with hematologic malignancies who
underwent double-unit CBT (DUCBT) with an antithymocyte globulinecontaining regimen at our insti-
tution. A subset of 65 patients was prospectively evaluated for recovery of T, natural killer (NK), and B cells,
and in 46 patients we also examined viral-speciﬁc T cell recovery against adenovirus, Epstein-Barr virus,
cytomegalovirus, BK virus, respiratory syncytial virus, and inﬂuenza antigen. Our results indicate that in
recipients of DUCBT, the day 30 absolute lymphocyte count is highly predictive of nonrelapse mortality and
overall survival. Immune recovery post-DUCBT was characterized by prolonged CD8þ and CD4þ T lym-
phopenia associated with preferential expansion of B and NK cells. We also observed profound delays in
quantitative and functional recovery of viral-speciﬁc CD4þ and CD8þ T cell responses for the ﬁrst year
post-CBT. Taken together, our data support efforts aimed at optimizing viral-speciﬁc T cell recovery to
improve outcomes post-CBT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Umbilical cord blood (CB) is being increasingly used as
a source of hematopoietic stem and progenitor cells for
allogeneic stem cell transplant candidates lacking suitable
matched donors. Although CB transplantation (CBT) is
successful in many patients, its efﬁcacy has been restricted
by slow hematopoietic and immunologic reconstitution
because of the quantitative and qualitative differences in
the composition of CB grafts [1-5]. Although the frequencyedgments on page 1289.
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ty for Blood and Marrow Transplantation.of hematopoietic stem and progenitor cells is greater in CB
units, CB grafts contain an average of 1 to 2 logs fewer
total cells compared with peripheral blood (PB) or bone
marrow allografts. Moreover, the vast majority of T, B, and
dendritic cells in CB grafts are immature [6,7], which likely
explains the low rates of graft-versus-host disease (GVHD)
seen after CBT given the degree of HLA mismatches typi-
cally used [8,9]. The use of dual CB grafts represents a
potentially important approach to reducing nonrelapse
mortality (NRM) among patients undergoing double unit
CBT (DUCBT), particularly in adult patients. In this setting,
although 2 CB units are initially transplanted, only 1
provides prolonged engraftment and becomes the
“dominant” engrafted unit. Yet, even after DUCBT, severe
complications related to infections remain a major cause
of morbidity and mortality [10-15]. Although this may be a
Table 1
Patient Characteristics (N ¼ 125)
Characteristic Value























AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leu-
kemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic
leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma;
MM, multiple myeloma; CR, complete remission; CP, chronic phase;
Bu, busulfan; Clo, clofarabine; Flu, ﬂudarabine; TBI, total body irradi-
ation; FM, ﬂudarabine and melphalan; MMF, mycophenolate mofetil.
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reﬂects the relative immaturity of CB immune subsets.
A number of studies have reported on immune reconsti-
tution after single CBT [16-20], but few have studied immune
recovery after DUCBT [21-23]. Here we report the results of a
prospective longitudinal study of immune recovery and
viral-speciﬁc T cell reconstitution in recipients of double CB
grafts. Our results indicate that the day 30 absolute
lymphocyte count (ALC30) is highly predictive of NRM and
overall survival (OS) in recipients of DUCBT who receive
serotherapy for GVHD prophylaxis and that recovery of
quantitative T cells as well as recovery of functional (cyto-
kine-producing) viral-speciﬁc T cells is delayed.METHODS
Patient Selection and Management
One hundred twenty-ﬁve consecutive adult patients undergoing DUCBT
at our institution from January 2006 to November 2011 were studied
(Table 1). Less than half of the patients (45%) were in ﬁrst or second complete
remission or ﬁrst or second chronic phase disease, whereas the rest had
advanced disease at the time of transplant. Informed consent was obtained
from all patients in accordance with the Declaration of Helsinki for protocols
approved by the MD Anderson Cancer Center Institutional Review Board.
All patients received serotherapy with rabbit thymoglobulin 1.25 mg/kg
on day 4 and 1.75 mg/kg on day 3. GVHD prophylaxis consisted of
tacrolimus and mycophenolate mofetil (1 g p.o. twice daily), with a taper of
mycophenolate mofetil at day 100 and tacrolimus at 6 months if no GVHD
was present. In the event of conﬁrmed or suspected GVHD, initial therapyTable 2
Donor Engraftment at Days þ30 and þ100 Post-DUCBT
Day þ30
Total T Cell Myeloid Cell
Overall 100% (97-100) 100% (100) 100% (99-100)
CB1 82% (39-100) 99% (75-100) 91% (42-100)
CB2 0% (0-31) 0% (0-16) 0% (0-28)
Donor engraftment for total, T cell, and myeloid cell fractions are presented as meconsisted of methylprednisolone (2 mg/kg/day), with a taper based on
clinical response.
The surveillance for cytomegalovirus (CMV) was performed by anti-
genemia assay in patients with absolute neutrophil counts > 1000/mL or
with quantitative PCR if the absolute neutrophil count was lower. This was
done twice weekly for the ﬁrst 100 days after CBT or longer if any compli-
cations were present. Other viruses including adenovirus (AdV), Epstein-
Barr virus (EBV), BK virus (BKV), respiratory syncytial virus (RSV), human
herpesvirus 6, inﬂuenza, and parainﬂuenza were tested as clinically indi-
cated. Donor engraftment was assessed using PCR with primer sets ﬂanking
microsatellite repeats.
Immunophenotyping
Immunophenotyping was performed by the ﬂow laboratory at MD
Anderson Cancer Center on PB samples collected at days þ30, þ100,
and þ180 and 1 year post-CBT. PB mononuclear cells were surface stained
with monoclonal antibodies against CD3, CD4, CD8, CD19, and CD56
(all from BD Biosciences, San Jose, CA). Cells were acquired on a Cyan ﬂow
cytometer (Dako, Fort Collins, CO) and data analyzed with FlowJo software
(Tree Star, Ashland, OR).
Enzyme-Linked Immunospot Assay
In a subset of 46 patients, IFN-g enzyme-linked immunospot analysis was
used to quantitate the frequency of T cells that secreted IFN-g in response to
hexon and penton (Adv); IE1 and pp65 (CMV); EBNA1, EBNA3a-c, LMP1,
LMP2, and BZLF1 (EBV); VP1 and large T (BKV); N and F (RSV); and MP1 and
NP1 (inﬂuenza) pepmixes (JPT Peptide Technologies GmbH, Berlin, Germany),
all diluted to 1 mg/mL per peptide. Staphylococcal enterotoxin B (1 mg/mL;
Sigma-Aldrich, Spring, TX) was used as positive control. PBmononuclear cells
collected before and after transplant were resuspended at 2 106/mL in T cell
media (Advanced RPMI 1640 [Life Technologies, Grand Island, NY] supple-
mented with 45% Click’s medium [Irvine Scientiﬁc, Santa Ana, CA], 2 mM
GlutaMAX [Life Technologies], and 10% FBS [Hyclone, Logan, UT]). Each con-
dition was run in duplicate. After 20 hours of incubation, plates were devel-
oped, dried overnight at room temperature in the dark, and then sent to
Zellnet Consulting for quantiﬁcation. Spot-forming cells (SFCs) and input cell
numbers were plotted, and the frequency of T cells speciﬁc to each antigen
was expressed as speciﬁc SFC per input cell numbers.
Statistical Analyses
Actuarial OS was estimated using the Kaplan-Meier method. The cu-
mulative incidence of NRM was estimated considering disease progression
or death attributable to malignancy as competing risks. Predictors of NRM
were evaluated in landmark analysis using Cox proportional hazards
regression analysis. Engrafted patients who were alive and progression-free
on the date ALC30 was measured were eligible for the risk factor analysis.
ALC30 was evaluated in quartiles. All analyses were performed using STATA
11 (StataCorp LP, College Station, TX), and statistical signiﬁcancewas deﬁned
at the .05 level.
RESULTS
Clinical Characteristics and Clinical Outcome
One hundred twenty-ﬁve adult patients with high-risk
hematologic malignancy who underwent DUCBT during
the study period were assessed, with a median follow-up of
979 days (range, 56 to 1907) in surviving patients. Details of
the conditioning regimens are included in Table 1. Thirty
percent of patients received 2 unmanipulated CB units, and
70% received 1 unmanipulated and 1 CB unit that was
expanded before infusion as previously described [24].
Successful neutrophil engraftment, as deﬁned by the
ﬁrst date of 3 consecutive days of absolute neutrophil count
 .5109/L, was achieved in 110 patients, whereas 9 patientsDay þ100
Total T Cell Myeloid Cell
100% (100) 100% (100) 100% (100)
99% (60-100) 100% (69-100) 100% (55-100)
0% (0-16) 0% (0-4) 0% (0-15)
dian percentages, with interquartile range in parentheses.
Table 3
Predictors of NRM by Univariate and Multivariate Analyses
Total* (n ¼ 108) Univariate Multivariate
3-Year HR 95% CI P 3 Year HR 95% CI P
ALC30 (106/L), quartiles
150 35 Ref.
>150-250 22 .4 .2-1.02 .05
>250-400 22 .5 .2-1.2 .1
>400 29 .4 .2-.9 .04
150 vs. >150 2.1 1.2-3.8 .01 2.3 1.3-4.1 .01
Diagnosis
AML 57 Ref.
ALL 17 2.2 1.1-4.7 .03
CML/CLL 3/13 .8 .3-2.1 .7
NHL/HL/MM 18 1.1 .5-2.6 .8
ALL vs. all other 2.3 1.2-4.5 .02 2.6 1.3-5.1 .01
Acute GVHD grades II-IV before day 30
No 89 Ref.




Female 55 1.6 .9-2.8 .1 N/A
Age, yr
45 51 Ref.
>45 57 1.2 .7-2.1 .5 N/A
50 61 Ref.
>50 47 .9 .5-1.5 .6 N/A
55 76 Ref.
>55 32 .9 .4-1.7 .7 N/A
Disease status
CR1/CP1 19 Ref. N/A
CR2/CP2 29 2.1 .8-5.3 .1
Advanced disease 60 1.5 .6-3.6 .4
CR1/CP1 vs. all other .6 .2-1.4 .2
Total nucleated cell dose infused
QRT1 30 Ref. N/A
QRT2 23 1.3 .6-3.1 .5
QRT3 28 1.2 .5-2.6 .7
QRT4 27 1.6 .5-2.6 .7
QRT1 vs. >QRT1 .8 .4-1.6 .5
Total CD34 dose infused
QRT1 26 Ref. N/A
QRT2 26 1.2 .5-2.9 .7
QRT3 28 1.4 .6-3.2 .4
QRT4 28 1.1 .5-2.7 .8
QRT1 vs. >1 .8 .4-1.6 .5
Recipient CMV serostatus
Reactive 95 1.1 .4-2.8 .8 N/A
Nonreactive 13 Ref.
HR indicates hazard ratio; QRT, quartile.
* Excluded from this analysis are patients who had primary graft failure or who died or progressed before ALC30 was measured.
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patients before donor engraftment could be evaluated. The
median times to neutrophil and platelet engraftment were
15 days (range, 4 to 45) and 36 days (range, 7 to 126),
respectively. Donor engraftment data at day 30 were
assessable for 92 patients (Table 2) and revealed predomi-
nance of a single CB unit in 41 patients, whereas 50 patients
had evidence of persistent host hematopoiesis. In 65
patients, full donor engraftment was achieved with a com-
bination of both CB units. One patient could not be assessed
because of delayed engraftment. At day 100 post-DUCBT, the
median percent of donor-derived cells detected from the
dominant unit was 100% (n ¼ 70), ranging from 14% to 100%
(interquartile range, 82% to 100%).
Predictors of NRM and OS
One hundred eight engrafted patients were eligible for
assessment of predictors of 3-year NRM in a landmark
analysis starting on day 30. In univariate analysis, 2 factorsthat signiﬁcantly affected NRM were ALC30, treated as
dichotomous variables above or below 150  106/L (upper
limit of ﬁrst quartile) and a diagnosis of acute lymphoblastic
leukemia. Median ALC30was 240 106/L (range,10 to 2420).
There was no signiﬁcant impact of age, sex, disease stage at
the time of DUCBT, CMV serostatus, the occurrence of grades
II to IV acute GVHD before day 30, total nucleated cell dose,
total CD34 dose, preparative regimen, or CB manipulation on
NRM (Table 3). In multivariate analysis, ALC30 (hazard ratio,
2.3; P ¼ .01) and diagnosis of acute lymphoblastic leukemia
(hazard ratio, 2.6; P ¼ .007) emerged as independent factors
strongly associated with NRM.
Figure 1 shows the impact of ALC30 on NRM and OS in all
patients. For patients with ALC30> 150 106/L, OS at 3 years
was 37% (95% conﬁdence interval [CI], 25% to 49%) compared
with 25% (95% CI, 11% to 40%) for those with counts  150 
106/L (P ¼ .02). Similarly, ALC30 > 150  106/L was related to
a lower risk of NRM, 42% (95% CI, 31% to 56%) versus 59% (95%
CI, 44% to 78%) (P¼ .01) in patients with ALC30 150 106/L.
Figure 1. Survival outcome based on ALC30. Impact of ALC30  or > 150  106/L on (A) OS and (B) NRM.
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versus ALC30> 150) included infections (50% versus 52%, P¼
.9) and GVHD (40% versus 30%, P ¼ .5). There were no dif-
ferences in the type of infections noted between the groups.
Moreover, there was no signiﬁcant impact of ALC30 on the
rate of grades II to IV acute GVHD (P¼ .4), disease progression
(P ¼ .7), or progression-free survival (P ¼ .07) at 2 years
(Table 4).
Lymphocyte Subset Analysis
In 65 patients for whom PB samples had been collected at
days þ30, þ100, and þ180 or 1 year post-DUCBT, we further
characterized immune subset recovery by measuring the
frequencies and absolute numbers of CD4þ T cells, CD8þ T
cells, CD56þCD3 natural killer (NK) cells, and CD19þ B cells
(Figure 2). The absolute number of each cell subset was
calculated by multiplying their frequencies as determined by
ﬂow cytometry by the absolute lymphocyte number (cells/
mL) obtained from a diagnostic complete blood count per-
formed on the same day. Lymphocyte reconstitution after
DUCBT began with a rapid increase in both the absolute
number and frequencies of NK cells over baseline norms and
remained increased at the different study intervals, although
the percentage of NK cells declined as T cell counts recov-
ered. The absolute B cell recovery followed a similar pattern
to NK cells, with an initially rapid recovery followed by a
return to baseline by 1 year post-DUCBT. T cell reconstitution,
on the other hand, was delayed. CD4þ and CD8þ T cells
declined after conditioning and were signiﬁcantly reduced
by day 30 post-DUCBT. The median absolute number of CD8þ
cytotoxic T cells was 6 106/L (range, 0 to 170) at 30 days and
11106/L (range, 0 to 1900) at 100 days post-transplant. The
corresponding numbers of CD4þ helper Tcells were 4106/L
(range, 0 to 100) and 22  106/L (range, 0 to 390),
respectively.Table 4
Impact of ALC30 on Disease Progression and Acute GVHD Outcomes at 2
Years
ALC30 Progression PFS Grades II-IV
Acute GVHD
HR 95% CI P HR 95% CI P HR 95% CI P
QRT1 Ref. Ref. Ref.
QRT2 1.3 .5-3.7 .6 .7 .4-1.2 .2 .8 .3-1.9 .6
QRT3 1.1 .4-3.3 .8 .7 .4-1.3 .3 .9 .4-2.0 .8
QRT4 1.1 .4-2.9 .9 .6 .3-1.1 .09 .6 .2-1.4 .2
QRT1 vs. all other .85 .4-1.9 .7 1.5 .96-2.4 .07 1.3 .7-2.6 .4
PFS indicates progression-free survival.These results conﬁrm that quantitative T cell recovery is
delayed after DUCBT, with an inverted CD4/CD8 T cell ratio,
and that this delay in T cell immunity is associated with a
preferential rapid reconstitution of noneT lymphoid cells
(eg, NK cells and B cells). Patients who developed acute
GVHD had a slower T and B cell recovery (data not shown), in
keeping with previous reports after allogeneic stem cell
transplantation [25].Viral Infections and Viral-Speciﬁc T Cell Recovery Post-
CBT
Functional immune reconstitutional studies were per-
formed under a protocol approved by Baylor College of
Medicine Institutional Review Board. To assess the tempo of
functional virus-speciﬁc T cell recovery after DUCBT, we
stimulated PB mononuclear cells from 46 transplant re-
cipients with 15-mer overlapping peptides spanning T cell
immunogenic antigens from a range of both latent (CMV,
EBV, BKV) and community (AdV, inﬂuenza, RSV) viruses as
well as to staphylococcal enterotoxin B, which was used as a
positive control. Before transplant the frequency of T cells
reactive against staphylococcal enterotoxin B was highest
(mean, 424.5 SFCs/2  105 PB mononuclear cells), followed
by CMV (mean, 258 SFCs in 39 seropositive donors), EBV
(mean, 33 SFCs), AdV (mean, 17 SFCs), BKV (mean, 13 SFCs),
inﬂuenza (mean, 8 SFCs), and RSV (mean, 10 SFCs) (Figure 3).
As shown in Figure 3A,B, T cell activity against staphylococcal
enterotoxin B, CMV, EBV, and AdV was delayed for at least 8
to 9 months after DUCBT (means of 200, 89, 28 and 24 SFCs/
2  105, respectively), whereas activity against BKV, inﬂu-
enza, and RSV was even further delayed (Figure 3C).
To assess whether delayed functional viral-speciﬁc T cell
recovery had clinical consequences in these 46 patients, we
correlated viral-speciﬁc immune recovery with viral in-
fections after DUCBT. Most patients (72%) assessed for
functional recovery developed viral infections/reactivations
post-DUCBT (summarized in Table 5). The most common
causes of viral infectionwere CMV (59%), BKV (20%), and AdV
(11%). Most of these infections occurred within the ﬁrst 100
days after DUCBT, and nearly 50% of patients had infections
with multiple viruses. Within the constraints of a relatively
small number of patients assessed, we did not observe a
difference in ALC30 among patients who did or did not
develop viral infections/reactivations post-DUCBT. Similarly,
we did not ﬁnd any differences in patients who acquired
infections and those who did not with respect to their viral
immune reconstitution.
Figure 2. Prolonged T lymphopenia and relative expansion of NK cells and B cells after DUCBT. T (CD3þCD4þ and CD3þCD8þ), B (CD19þ), and NK (CD56þ) cells were
prospectively measured by multiparameter ﬂow cytometry on fresh samples. (A) Frequencies and (B) absolute numbers (106/L) for each immune subset are
presented. At baseline and after DUCBT, CD4þ and CD8þ T cells were relatively reduced, whereas early B cell and NK cell recovery was evident. Surviving CBT re-
cipients demonstrated rebound of CD4þ and CD8þ T cells at later intervals after transplantation. Error bars represent interquartile range.
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Our study of 125 consecutive adult patients receiving
DUCBT with a median follow-up of 32 months is the largest
series to date reporting on the signiﬁcance of lymphocyte
recovery and the kinetics of immune reconstitution and
viral-speciﬁc T cell immunity in this setting. Despite the
heterogeneity of this population, this study conﬁrmsFigure 3. Virus-speciﬁc T cell activity after DUCBT. (A) Frequencies of staphylococcal
cells; (B) frequency of CMV (IE1 and pp65)-speciﬁc T cells in seropositive and seronega
EBNA3c, BZLF1), inﬂuenza (MP1 and NP1), and RSV (N and F) reactive T cells in PB sam
immunospot as readout. Each symbol represents an individual patient and results reprevious reports of early lymphocyte recovery as a prog-
nostic factor for outcome after CBT [22,26-32].
Lymphocyte subset analysis in 65 patients revealed that
CD4þ and CD8þ T cell reconstitution was signiﬁcantly
delayed, when compared with reported recovery in re-
cipients of matched sibling or matched unrelated donor
hematopoietic stem cell transplantation recipients, inenterotoxin B, BKV (large T and VP1), and AdV (hexon and penton)-reactive T
tive donors; and (C) frequencies of EBV (LMP1, LMP2, EBNA1, EBNA3a, EBNA3b,
ples collected from patients before and after DUCBT using IFN-g enzyme-linked
present SFCs/2  105 input cells.
Table 5
Viral Reactivation or Infection in 46 Patients after DUCBT in Whom Viral-
Speciﬁc T Cell Recovery Was Examined










CMV 19 8 31 13-77
BKV 9 - 48 12-97
HHV6 2 - 66
Parvovirus - 1 69
AdV 2 3 70 44-85
HSV - 1 139
EBV - 2 254
RSV - 1 425
Parainﬂuenza 1-3 1 3 455 98-1237
Inﬂuenza B - 1 799
Total number of
incident infections
33 20 44 12-1237
Number of Different







Total patients with at least 1
type of viral infection
33 100%
HHV6 indicates human herpesvirus 6; HSV, herpes simplex virus.
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tients in the setting of single or double CBT [16,21-23,33].
Ruggeri et al. [21] reported on clinical outcome and immune
recovery in 35 patients with high-risk hematologic diseases
undergoing DUCBT. Immune reconstitution studies,
including measures of thymopoiesis as assessed by T cell
receptor excision circle analysis, revealed delayed T cell re-
covery for the ﬁrst 9 months post DUCBT [21]. Studies in the
nonmyeloablative DUCBT setting by Somers et al. [23]
revealed early T and NK cell engraftment, followed by pre-
dominance of myeloid cells by day 18.
As a direct consequence of delayed immune recovery,
recipients of CBT are at signiﬁcant risk of opportunistic in-
fections, particularly viral infections including CMV, EBV,
AdV, and BKV [34-37]. Indeed, when we prospectively and
longitudinally assessed the frequency of functional virus-
directed T cells directed against a range of immunogenic
CMV (IE1, pp65), EBV (EBNA1, EBNA3a, 3b,3c, LMP1, LMP2,
BZLF1), BKV (VP1, LT1), AdV (hexon and penton), inﬂuenza
(MP1, NP1), and RSV (N and F) antigens, we saw a signiﬁcant
delay (9 to 12 months) in the recovery of IFN-gesecreting
precursors, demonstrating the inability of immature CB T
cells to initiate early primary immune responses to patho-
gens. This explains the high rates of viral infections observed
associated with post-DUCBT. Interestingly, the observation
that in the early post-transplantation period most PB lym-
phocytes are NK cells, which can mediate cytotoxicity
without prior sensitization, suggests that NK cells may be
responsible for protection against viral reactivation early
after CBT.
DUCBT is associated with a higher rate of aGVHD than
single CBT [38]. In our cohort the incidence of acute GVHD
grades II to IV was around 40%. Acute GVHD and its treat-
ment with corticosteroids and other immunosuppressive
agents may account for some of the delay in immune
reconstitution seen after DUCBT. To improve engraftment
and limit GVHD, we used in vivo T cell depletion with
antithymocyte globulin (ATG) in all our conditioningregimens, which likely contributes further to delayed T cell
recovery. The impact of ATG on infection outcomes after CBT
is debated in the absence of a randomized trial. Although
some studies suggest an increased risk of opportunistic in-
fections and viral reactivations with the use of high-dose
ATG after reduced-intensity conditioning regimens, a
similar association was not observed after myeloablative
conditioning regimens [35]. Other studies using ATG did not
reveal increased risk of infections after CBT [4,39]. More
recently, use of high-dose rabbit ATG in pediatric patients
undergoing CBT was shown to be associated with lower
incidence of acute GVHD at the expense of higher rate of
viral infections [39].
Taken together, our results conﬁrm that delayed immune
reconstitution, and consequently infections, remain major
complications after DUCBT when compared with HLA-
matched marrow or PB progenitor cell transplantation,
with slower quantitative recovery of T lineage immune cell
populations and more rapid NK and B cell reconstitution
[3,22,38,40]. This information is essential to improve our
understanding of immune reconstitution and to develop
strategies to accelerate immune recovery after CB trans-
plantation. Our group is exploring a number of novel
approaches in preclinical and clinical studies, such as ex vivo
graft manipulation and the use of adoptively transferred
viral-speciﬁc mature T cells [24,41], to improve immune
reconstitution and clinical outcomes in patients undergoing
CBT.
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